End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
180,900 KRW | +0.72% | -2.85% | -10.22% |
05-24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
05-10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.22% | 27.4B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.52% | 39.2B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B | |
-9.26% | 11.05B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion Provides Earnings Guidance for the Year 2017